SIETES :: 92826 citas

Resultados de la búsqueda por HEMATOLOGÍA REFINAR BÚSQUEDA

1.

Conte C, Despas F. Le beau mois de Juin des inhibiteurs de protéines kinases. BIP Occitanie 2019;26:junio. [Ref.ID 103136]

2.

Garmendia CA, Gorra LN, Rodríguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses. The example of the apixaban trials. JAMA Intern Med 2019;179:4 de marzo. [Ref.ID 103094]

3.

Jones G. Orphan drugs market to soar to $224bn by 2024. Cell and gene therapies to fuel growth. PMLiVE 2019:25 de abril. [Ref.ID 103080]

4.

Pinto T. Los nuevos anticoagulantes obligan a las farmacéuticas a pagar cientos de millones para evitar juicios . eldiario.es 2019:31 de marzo. [Ref.ID 103065]

5.

Anónimo. Létermovir et prévention d'une réactivation du cytomégalovirus. Prescrire 2018;38:895-8. [Ref.ID 102905]

6.

Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, Stein M. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA 2018;320:4 de diciembre. [Ref.ID 102867]

7.

Belmonte E, Bernardo A. 18 médicos recibieron más de 50.000 euros cada uno de una sola farmacéutica en 2017 . eldiario.es 2018:10 de octubre. [Ref.ID 102835]

8.

Álvarez del Vayo M. Las asociaciones de pacientes recibieron casi seis millones de euros de la industria farmacéutica en 2016. CIVIO Medicamentalia 2018:19 de abril. [Ref.ID 102833]

9.

Moore TJ, Hanzhe Z, Anderson G, Alexander C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018:24 de septiembre. [Ref.ID 102831]

10.

Huang W-Y, Singer DE, Wu J-L, Chiang C-E, Weng H-H, Lee M, Ovbiagele B. Association of intracranial hemorrhage risk with non–vitamin K antagonist oral anticoagulant use vs aspirin use. A systematic review and meta-analysis. JAMA Neurology 2018:13 de agosto. [Ref.ID 102795]

11.

Mitchell AP, Winn AN, Dusetzina SB. Pharmaceutical industry payments and oncologists’selection of targeted cancer therapies in Medicare beneficiaries. JAMA Intern Med 2018;178:junio. [Ref.ID 102773]

12.

Anónimo. Inotuzumab ozogamicine et leucémie aiguë lymphoblastique chez les adultes. Prescrire 2018;38:494-9. [Ref.ID 102757]

13.

Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ 2018;361:4 de julio. [Ref.ID 102751]

14.

Anónimo. Novartis, Gilead CAR-T therapies both gain European panel recommendation. DIA Daily 2018:2. [Ref.ID 102703]

15.

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: A retrospective cohort study. Br J Clin Pharmacol 2018;84:marzo. [Ref.ID 102649]

16.

Adderley NJ, Nirantharakumar K, Marshall T. Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. BMJ 2018;360:9 de mayo. [Ref.ID 102644]

17.

Ross JS, Krumholz HM, Hines Jr HH. Bringing Vioxx back to market. BMJ 2018;360:k242. [Ref.ID 102639]

18.

Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378:24 de mayo. [Ref.ID 102636]

19.

Patel TK, Patel TB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol 2018;74:junio. [Ref.ID 102626]

20.

Anónimo. Edoxaban: Interstitial lung disease. Japan . WHO Drug Information 2018;32:18. [Ref.ID 102620]